Strategic partnerships are an integral part of our model. We value collaboration with companies and institutions at the forefront of scientific innovation and we are focused on building robust relationships and alliances in the service of helping patients in need.

We seek academic and industry partners, both within the United States and globally, committed to making life-changing medicines as rapidly and safely as possible. Additionally, we are open to discussing portfolio divestments and licensing of pharmaceutical assets.

BridgeBio is seeking partners for the following programs:

  • BBP-589 – Recombinant collagen 7 for dystrophic epidermolysis bullosa (rDEB)
    • Completed Phase 2 clinical trial designed to evaluate safety and tolerability of BBP-589, as well as clinical proof-of-concept, and initiated a Phase 2 extension study
  • BBP-681 – Topical PI3KA inhibitor for venous and lymphatic malformations (VM and LM)
    • Phase 1/2 clinical trial underway
  • BBP-711 – GO inhibitor for primary hyperoxaluria type 1 (PH1) and recurrent kidney stone formers
    • Phase 1 clinical trial completed
  • BBP-398 – SHP2 inhibitor for MAPK/RAS driven cancers
  • BBP-561 – KLK 5/7 inhibitor for Netherton syndrome
    • Investigational New Drug (IND) enabling studies underway
  • BBP-631 – Adeno-associated virus (AAV) 5 gene therapy for congenital adrenal hyperplasia (CAH)
    • Phase 1/2 clinical trial underway
  • BBP-818 – AAV gene therapy for classic galactosemia
    • IND-enabling studies underway
  • BBP-815 – AAV gene therapy for nonsyndromic hearing loss 
    • Preclinical development
  • BBP-472 – PI3KB inhibitor for PTEN autism
    • Preclinical development

Contact [email protected] for more information

licensing opportunities